BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded ...

In a report released yesterday, Kallum Titchmarsh from Morgan Stanley maintained a Sell rating on Embecta Corporation (EMBC – Research Report), ...

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

After adding nearly 30% in the previous session following its better-than-expected Q4 results for FY24, Embecta (NASDAQ:EMBC) ...

Q4 2024 Earnings Call Transcript November 26, 2024 Embecta Corp. misses on earnings expectations. Reported EPS is $ EPS, ...

Embecta Corp (EMBC) reports a 4.1% revenue increase while navigating restructuring and future growth opportunities.

PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference ...

AQR Capital Management LLC lifted its stake in shares of Embecta Corp. (NASDAQ:EMBC – Free Report) by 136.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC.

embecta Corp. (embecta) (Nasdaq: EMBC), a global diabetes care company, visits the Nasdaq MarketSite in Times Square today in recognition of National Diabetes Awareness Month in November.